… ProQR Announces Japanese Axiomer™ Patent Upheld Following … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … 2023 with the Japanese Patent Office by a strawman against ProQR’s granted patent JP 7244922 , which is related to the …
… ProQR to Present its Axiomer® RNA Editing Technology at the … & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … USA, that is being held May 9-12, 2022 in Boston, MA, U.S. ProQR presentation Presentation title: Development of RNA …
… ProQR Announces Top-Line Results from Phase 2/3 Illuminate … Daniel A. de Boer, Founder and CEO of ProQR Therapeutics. “ProQR was founded with the goal of developing RNA therapies … many are feeling in the community,” said Benjamin R. Yerxa, Chief Executive Officer at the Foundation Fighting …
… ProQR Announces First Patients Dosed in Phase 2/3 Pivotal … & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … testing,” said Aniz Girach, M.D., Chief Medical Officer of ProQR. “In a previous clinical study, QR-421a appeared to be …
… ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial … and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research & Development of ProQR, said, “QR-1123 aims to block expression of the toxic …